Pfizer Inc. and partner BioNTech SE have submitted data to U.S. health regulators needed to clear a Covid-19 booster shot among the general public. The companies said Monday they sent to the U.S. Food and Drug Administration results from a small, early-stage study showing a third dose of their vaccine generated higher levels of neutralizing antibodies against the original virus and against the Beta and Delta variants than the standard two-dose regimen.
Read more here.
